Biomarker Identification of Radionuclide Therapy-induced Radiation Responses (Radio-Marker)
Primary Purpose
Neuroendocrine Tumors
Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Lutathera
Sponsored by
About this trial
This is an interventional basic science trial for Neuroendocrine Tumors
Eligibility Criteria
Inclusion Criteria:
- Patient with an advanced, well-differentiated midgut neuroendocrine tumor.
- Indication for treatment with PRRT with 7.4 GBq 177Lu-DOTATATE as determined by the multidisciplinary team.
- Age ≥ 18 years.
Exclusion Criteria:
- Failure to obtain informed consent.
- Patient received IR for imaging purposes within one week prior to PRRT or IR for therapeutic purposes within 3 months prior to PRRT.
- Previous treatment with PRRT.
- Indication to receive another activity of PRRT than 7.4 GBq.
Sites / Locations
- Erasmus MCRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Peptide receptor radionuclide therapy
Arm Description
PRRT 4x7.4GBq
Outcomes
Primary Outcome Measures
Transcriptional regulation and DNA damage induction in PBMCs after PRRT.
DNA damage will be assessed by immunofluorescent stainings and microscopic detection of γ-H2AX and 53BP1 RIF. RIF numbers of at least 50 cells from at least 4 fields of view per blood sample will be quantified using an automated quantification macro in ImageJ.
RNA isolation, sequencing, analysis and qPCR validation will be done. Validation of the identified differentially expressed genes will be performed in triplicate by qPCR. For sequencing, we will use an unique in-house analysis method using a Snakemake pipeline. RIF and sequencing analysis will be performed on blinded samples to perform unbiased analysis.
Secondary Outcome Measures
mimic transcriptional regulation and DNA damage induction in PRRT ex vivo.
Untreated blood from the patient will be treated with 177Lu-DOTATATE ex vivo. Analysis of transcriptional regulation and DNA damage induction will be done as mentioned in the description of outcome 1.
detection of ctDNA in NET patients
For the assessment of circulating biomarkers of the tumor cells we will measure ctDNA levels in the blood.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05513469
Brief Title
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
Acronym
Radio-Marker
Official Title
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2023 (Actual)
Primary Completion Date
October 1, 2024 (Anticipated)
Study Completion Date
October 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-[Tyr3]octreotate (177Lu-DOTATATE) is a form of internal radiation treatment for patients with neuroendocrine tumors (NET) to reduce tumor growth and stabilize disease. Due to limited response rates, there is a need to improve this therapy. A better understanding of therapeutic radiobiological responses, such as transcriptional and DNA damage responses, could contribute to identification of biomarkers for toxicity and/or efficacy prediction. Easy access to biological samples for biomarker discovery would be via a so-called liquid biopsy (drawing blood) to collect healthy peripheral blood mononuclear cells (PBMCs) or circulating tumor DNA (ctDNA) for further investigation.
Exposure to ionizing radiation (IR) such as by PRRT leads to complex cellular responses including activation of the DNA damage response and changes in gene expression which can differ between individuals. This was previously shown for ex vivo external beam radiation of blood cells in which radiation responsive genes were identified. These genes were also similarly up- or downregulated following in vivo exposure to total-body irradiation of patients. In addition, different studies have shown a good correlation between radiation dose to the blood and DNA double strand break induction in PBMCs for various PRRT-like treatments. These results show that such events can be measured in PBMCs and indicate that ex vivo irradiation can mimic the in vivo transcriptional regulation and DNA damage induction. Therefore, to identify PRRT-induced cellular responses, the investigators will analyze the effects of 177Lu-DOTATATE IR on the transcriptional regulation in PBMCs and compare this regulation to radiation dose and DNA damage induction.
In addition, it was shown that levels of ctDNA can be associated with treatment response and anticancer treatment is also shown to influence ctDNA methylation patterns. The investigators will therefore explore dynamics of ctDNA levels and methylation patterns before and after PRRT to provide more knowledge of the effect of radiation response on ctDNA.
This is a pilot study to validate the possibility of determining the radiation response of PRRT with 177Lu-DOTATATE in PBMCs and ctDNA.
Detailed Description
Altogether, the PBMC and ctDNA analyses will provide essential information on the PRRT radiation response using blood as easily accessible material. Future research can focus on development of radiation response biomarkers based on the outcomes of this study.
Objective: This is a pilot study to validate the possibility of determining the radiation response of PRRT with 177Lu-DOTATATE in PBMCs and ctDNA.
Study design: Prospective translational study with additional blood collections at 4 timepoints during regular patient care for ex vivo characterisation.
Study population: Twenty patients with locally advanced or metastatic NET receiving the first PRRT cycle of 7.4 GBq 177Lu-DOTATATE.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Participants who receive standard PRRT will undergo 4 additional venipunctures during their scheduled stay in the hospital for PRRT administration. The burden of the venipunctures is minimal. There is no benefit for particitants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuroendocrine Tumors
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Peptide receptor radionuclide therapy
Arm Type
Other
Arm Description
PRRT 4x7.4GBq
Intervention Type
Drug
Intervention Name(s)
Lutathera
Other Intervention Name(s)
177lu-dotatate
Intervention Description
regulair PRRT of 4 cycles with 7.4GBq
Primary Outcome Measure Information:
Title
Transcriptional regulation and DNA damage induction in PBMCs after PRRT.
Description
DNA damage will be assessed by immunofluorescent stainings and microscopic detection of γ-H2AX and 53BP1 RIF. RIF numbers of at least 50 cells from at least 4 fields of view per blood sample will be quantified using an automated quantification macro in ImageJ.
RNA isolation, sequencing, analysis and qPCR validation will be done. Validation of the identified differentially expressed genes will be performed in triplicate by qPCR. For sequencing, we will use an unique in-house analysis method using a Snakemake pipeline. RIF and sequencing analysis will be performed on blinded samples to perform unbiased analysis.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
mimic transcriptional regulation and DNA damage induction in PRRT ex vivo.
Description
Untreated blood from the patient will be treated with 177Lu-DOTATATE ex vivo. Analysis of transcriptional regulation and DNA damage induction will be done as mentioned in the description of outcome 1.
Time Frame
2 years
Title
detection of ctDNA in NET patients
Description
For the assessment of circulating biomarkers of the tumor cells we will measure ctDNA levels in the blood.
Time Frame
2 years
Other Pre-specified Outcome Measures:
Title
Evaluate the effect of PRRT on ctDNA levels.
Description
ctDNA levels will be measured in the blood before PRRT and 8 weeks after the first cycle.
Time Frame
2 years
Title
methylation sequencing ctDNA
Description
DNA methylation sequencing method will be used to analyze the ctDNA. The MeD-seq assay will be used for genome-wide DNA methylation profiling on cell-free DNA (cfDNA)
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with an advanced, well-differentiated midgut neuroendocrine tumor.
Indication for treatment with PRRT with 7.4 GBq 177Lu-DOTATATE as determined by the multidisciplinary team.
Age ≥ 18 years.
Exclusion Criteria:
Failure to obtain informed consent.
Patient received IR for imaging purposes within one week prior to PRRT or IR for therapeutic purposes within 3 months prior to PRRT.
Previous treatment with PRRT.
Indication to receive another activity of PRRT than 7.4 GBq.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
M.N. Becx
Phone
43449
Email
m.becx@erasmusmc.nl
Facility Information:
Facility Name
Erasmus MC
City
Rotterdam
State/Province
South Holland
ZIP/Postal Code
3015 GD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erasmus N MC
Phone
43449
Email
m.becx@erasmusmc.nl
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
We'll reach out to this number within 24 hrs